Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Lansoprazole Capsules vs Enteric-coated Capsules in Healthy Chinese Volunteers
NCT03488186Phase 1Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lansoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Pharmacokinetics Assessment at Day 7 and Pharmacodynamics Assessment at Day 7. Started Jul 2018; status: completed.
02
Drugs
lansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03488186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03488186.